Seeking Alpha

Discovery Lab (DSCO -12.5%) tanks after saying the commercial launch of its Surfaxin liquid...

Discovery Lab (DSCO -12.5%) tanks after saying the commercial launch of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will likely be delayed until Q2 of 2013. Expectations had been for it to be released by the end of the year.
Comments (3)
  • mike dubs
    , contributor
    Comments (28) | Send Message
     
    This is very dissappointing as it suggests ineptitude persists even after the BAT-related delay on the QC side of Discovery Labs manufacturing team. The share price drop does tempt me to buy more, but the poor execution on commercialization of the drug continues to plague this company's promising prospects.
    24 Oct 2012, 02:48 PM Reply Like
  • labazaar
    , contributor
    Comment (1) | Send Message
     
    It's discouraging to see management, once again, drop the ball!!

     

    You would have thought that after years of gross missteps that they had finally got it right.

     

    I guess not...!!
    24 Oct 2012, 03:43 PM Reply Like
  • mike dubs
    , contributor
    Comments (28) | Send Message
     
    I expect the company to provide more clarity on this issue and management's plan to prevent such missteps in the future. It really is unacceptable.
    6 Nov 2012, 09:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|